Revolutionary Cancer Therapy Technology: Araris Biotech Receives the 2025 Strüngmann Award

The founding team of Swiss biotech company Araris Biotech has been honored with the prestigious Strüngmann Award 2025. The award recognizes outstanding scientific and entrepreneurial achievements in the life sciences sector in the DACH region.

The jury selected Dr. Dragan Grabulovski, Dr. Philipp Spycher, and Dr. Isabella Attinger-Toller for their proprietary technology platform for antibody-drug conjugates (ADCs). This groundbreaking method enables the production of highly precise therapeutics in a single step, without the need for chemical modification of antibodies.

Founded in 2019 as a spin-off from the Paul Scherrer Institute, Araris Biotech has secured strategic partnerships with pharmaceutical giants like Chugai (Roche) and Johnson & Johnson. In March 2025, the company was acquired by Taiho Pharmaceutical in a deal valued at up to USD 1.14 billion.

“We are deeply honored that our vision and achievements have been recognized with the Strüngmann Award,” said CEO Dr. Grabulovski. The founders emphasize that this recognition is not only a validation of their past work but also a boost for the next phase of innovation.

The Strüngmann Award was launched in 2024 to honor visionary entrepreneurs in the life sciences field. Named after twin entrepreneurs Dr. Andreas and Dr. Thomas Strüngmann, the award celebrates groundbreaking ideas with the potential to transform global healthcare.